The unfulfilled promise of melanoma vaccines

Clinical Cancer Research

Volumn 7, Issue 7, 2001, Pages 1837-1838

  Livingston, P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GD2; GANGLIOSIDE GD3; GANGLIOSIDE GM2; MELANOMA ANTIGEN; MELANOMA VACCINE;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CELL FRACTIONATION; CYTOKINE PRODUCTION; EDITORIAL; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; MELANOMA; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0034777876     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (11)

1. Double-blind trial of a polyvalent, shed antigen, melanoma vaccine
2. Selection of carbohydrate tumor antigens as targets for immune attack using immunohistochemistry. I. Focus on Gangliosides
3. The identification of cancer antigens: Impact on the development of cancer vaccines
4. Cancer vaccines
5. The case for melanoma vaccines that induce antibodies
6. The history of cancer immunotherapy
7. Identification of melanoma antigens that are immunogenic in humans and expressed in vivo
8. High dose interferon α-2b significanty prolongs relapse-free and overall survival compared with GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/S9512/C509801
9. Active-specific immunotherapy for melanoma
10. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine
11. Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases